Premium
Cancer Immunotherapy: PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy (Adv. Mater. 22/2018)
Author(s) -
Zhang Xudong,
Wang Chao,
Wang Jinqiang,
Hu Quanyin,
Langworthy Benjamin,
Ye Yanqi,
Sun Wujin,
Lin Jing,
Wang Tianfu,
Fine Jason,
Cheng Hao,
Dotti Gianpietro,
Huang Peng,
Gu Zhen
Publication year - 2018
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201870152
Subject(s) - immunotherapy , cancer immunotherapy , cancer , materials science , cancer therapy , cancer cell , blockade , immune system , cancer research , nanotechnology , receptor , immunology , medicine
In article number 1707112 , Peng Huang, Zhen Gu, and co‐workers engineer cellular nanovesicles presenting PD‐1 receptors on their membranes, which enhance antitumor response by disrupting the PD‐1/PD‐L1 immune inhibitory axis. These nanovesicles could also be adapted to carry a variety of therapeutics to achieve synergistic cancer therapy.